Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2003
12/02/2003US6656705 Sciellin and uses thereof
12/02/2003US6656704 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
12/02/2003US6656681 Polycystic kidney disease 12 gene and uses thereof
12/02/2003US6656679 Heat shock protein-based vaccines and immunotherapies
12/02/2003US6656481 Vaccinal preparations
12/02/2003US6656480 Nucleotide sequences which code polypeptide for use the treatment of mammary gland cancer
12/02/2003US6656479 Protects a mammal against neosporosis
12/02/2003US6656478 Cross-protective salmonella vaccines
12/02/2003US6656477 43 Kd protein vaccine and method for the production thereof
12/02/2003US6656476 Vaccine against Mumps containing a Jeryl-Lynn virus strain
12/02/2003US6656475 Modulating growth of muscle or adipose tissue in eukaryotic organism using agent that affects myostatin signal transduction
12/02/2003US6656474 Minimal adverse side effects
12/02/2003US6656472 Multi oligosaccharide glycoconjugate bacterial meningitis vaccines
12/02/2003US6656471 Monitoring HLA-Cw7-restricted CTL response; AIDS prevention
12/02/2003US6656470 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
12/02/2003US6656469 Treatment of nicotine dependence from tobacco products
12/02/2003US6656468 Such as botulinus antitoxin orally
12/02/2003US6656467 Genetic engineering; administering immunoglobulins
12/02/2003US6656462 Interleukin-1 muteins useful as vaccine adjuvants
12/02/2003CA2099268C Fusions of a viral protein and a destructive enzyme
12/02/2003CA2046904C Cd4 specific recombinant antibody
11/2003
11/30/2003CA2388456A1 Macroaggregated albumin-polyethyleneimine (maa-pei) lung-targeted delivery of respiratory syncytial virus dna vaccines
11/27/2003WO2003098223A2 A method for killing cells by inhibiting histone activity in the cell
11/27/2003WO2003098214A1 Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species
11/27/2003WO2003098212A2 Method of isolating an endotehelial cell and method of donor specific crossmatching
11/27/2003WO2003098211A1 Detection of autoantibodies to cytokeratin 18 protein in patients with bronchial asthma and chronic rhinitis, and its applications including a kit for diagnosing bronchial asthma and chronic rhinitis comprising mammalian cytokeratin 18 protein
11/27/2003WO2003097872A2 G - protein coupled receptor marker molecules associated with colorectal lesions
11/27/2003WO2003097852A2 Assay for identifying inhibitors of fc gamma riii signaling
11/27/2003WO2003097846A1 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
11/27/2003WO2003097845A1 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
11/27/2003WO2003097844A1 Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
11/27/2003WO2003097814A2 Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
11/27/2003WO2003097803A2 Cancer-linked gene as target for chemotherapy
11/27/2003WO2003097698A1 Treatment of cancer by the use of anti fas antibody
11/27/2003WO2003097688A2 Muteins of placental growth factor type 1, preparation method and application thereof
11/27/2003WO2003097686A1 Novel protein, its dna and use thereof
11/27/2003WO2003097677A2 Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus
11/27/2003WO2003097676A1 Polypeptide antigen inducing hiv neutralizing antibodies
11/27/2003WO2003097675A1 Fusion protein of hiv regulatory/accessory proteins
11/27/2003WO2003097663A2 Immunogenic, monoclonal antibody comprising at least 2 different epitopes of a tumor-associated antigen
11/27/2003WO2003097091A2 Glucan-based vaccines
11/27/2003WO2003097090A1 Use of modified novirhabdoviruses to obtain vaccines
11/27/2003WO2003097089A2 Attenuation of metapneumovirus
11/27/2003WO2003097087A1 Bcg vaccine and utilization thereof
11/27/2003WO2003097082A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
11/27/2003WO2003096974A2 ORIENTIA TSUTSUGAMUSHI TRUNCATED RECOMBINANT OUTER MENBRANE PROTEIN (r47) AND (r56) VACCINES DIAGNOSTICS AND THERAPEUTICS FOR SCRUB TYPHUS AND HIV INFECTION
11/27/2003WO2003096967A2 Dna vaccines encoding heat shock proteins
11/27/2003WO2003096812A1 Regulated attenuation of live vaccines to enhance cross protective immunogenicity
11/27/2003WO2003096782A2 Process for preparing maytansinol
11/27/2003WO2003085087A3 Modified cea nucleic acid and expression vectors
11/27/2003WO2003076598A3 Method of inducing an enhanced immune response against hiv
11/27/2003WO2003076469A3 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
11/27/2003WO2003075841A3 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
11/27/2003WO2003073981A3 Novel of cytokine inhibitors
11/27/2003WO2003072594A3 An obligate domain-swapped dimer of cyanovirin with enhanced anti-viral activity
11/27/2003WO2003072045A3 Treatment and prevention of aids progression and methods of using same
11/27/2003WO2003068974A3 YkuR POLYNUCLEOTIDES AND POLYPEPTIDES
11/27/2003WO2003068940A3 Complexes and methods of using same
11/27/2003WO2003066807A9 Method of inhibiting pathogenicity of infectious agents
11/27/2003WO2003066661A3 Human dr4 antibodies and uses thereof
11/27/2003WO2003064622A3 Aggrecanase molecules
11/27/2003WO2003061636A3 Dna dosage forms
11/27/2003WO2003061590A3 Peptide constructs for treating disease
11/27/2003WO2003057837A3 Methods for using anti-muc18 antibodies
11/27/2003WO2003055513A3 Bacillus subtilis spores to stimulate the immune responses
11/27/2003WO2003054004A3 Secreted proteins
11/27/2003WO2003053338A3 Novel chimeric rev, tat, and nef antigens
11/27/2003WO2003051383A3 Use of hmgb proteins and nucleic acids that code therefor
11/27/2003WO2003051288A3 Mycobacterial vaccine
11/27/2003WO2003043986A3 Polypeptides of moraxella (branhamella) catarrhalis
11/27/2003WO2003041651A3 Allatoin-containing skin cream
11/27/2003WO2003035696A3 Humanized antibodies against icam-1, their production and uses
11/27/2003WO2003031578A3 Mammalian c-type lectins
11/27/2003WO2003030932A9 Attenuated mutant newcastle disease virus strains for in ovo vaccination, method for preparing and their use
11/27/2003WO2003028656A3 Adjuvant compositions
11/27/2003WO2003024482B1 Crustaceans as production systems for therapeutic proteins
11/27/2003WO2003023023B1 Production and use of human cd124 and cd116 positive tumour cell lines in the production of allogenic or semi-allogenic immunotherapy agents
11/27/2003WO2003022868A3 Metal binding proteins and associated methods
11/27/2003WO2003020759A3 A caspase- 8 binding protein, its preparation and use
11/27/2003WO2003015713A3 Treatment of glial tumors with glutamate antagonists
11/27/2003WO2003013590A8 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
11/27/2003WO2003010195A3 Novel compounds
11/27/2003WO2003009817A3 Stable lyophilized pharmaceutical formulation of igg antibodies
11/27/2003WO2003008443A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/27/2003WO2003006995A3 Method for identifying substances which modulate interleukin 4 (il-4) signaling
11/27/2003WO2003006611A3 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE
11/27/2003WO2003001981A3 Method of promoting engraftment of a donor transplant in a recipient host
11/27/2003WO2002102299A3 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
11/27/2003WO2002099059A3 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
11/27/2003WO2002097041A3 Fusion proteins of biologically active peptides and antibodies
11/27/2003WO2002094881A3 Monoclonal antibody neutralising cathepsin b activity and uses thereof
11/27/2003WO2002092771A3 Specific binding proteins and uses thereof
11/27/2003WO2002092626A3 Cleavage and polyadenylation complex of precursor mrna
11/27/2003WO2002092004A8 Use of hmg fragment as anti-inflammatory agents
11/27/2003WO2002088361A3 Haemophilus influenzae antigens
11/27/2003WO2002086156A3 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
11/27/2003WO2002086113A3 Enzyme and snp marker for disease
11/27/2003WO2002085940A3 New polynucleotides and polypeptides of the erythropoietin gene
11/27/2003WO2002070006A8 Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
11/27/2003WO2002064791A3 Proteins and nucleic acids encoding same
1 ... 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 ... 1823